Register for a Biocartis Idylla live demonstration at ADIAP Conference
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.
08May
News
02Apr
Register for a Biocartis Idylla live demonstration at ASDG Conference
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.
25Feb
Idylla EGFR Mutation Test (CE-IVD)
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
20Feb
Register for a live demonstration at RCPA Pathology Update
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.
06Sep
Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
Press Release: Mechelen, Belgium, 27 June 2018
29Aug
Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).
11Jun
Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests
A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).